YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
(RTTNews) - Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision-oncology company, reported second quarter results, showing a narrower loss primarily driven by increased revenue and reduced Research and Development (R&D) co…
(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue…
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Ea…
(RTTNews) - Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision oncology company, priced its offering of 18.02 million shares at a price of $4.44 per share, and pre-funded warrants to purchase up to 2.25 million shares at…
The United States market has shown robust growth, rising 3.5% over the last week and 31% over the past year, with earnings expected to increase by 16% annually in the coming years. In such a thriving market, identifying stocks with strong…
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT137…
(RTTNews) - Prelude Therapeutics Incorporated (PRLD) reported full-year 2025 results and provided an update on its precision oncology pipeline, highlighting progress across its JAK2V617F mutant-selective inhibitor program and highly select…
* Prelude Therapeutics press release [https://seekingalpha.com/pr/20430368-prelude-therapeutics-reports-full-year-2025-financial-results-and-provides-program-outlook] (PRLD [https://seekingalpha.com/symbol/PRLD]): FY GAAP EPS of -$1.29 mis…
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the most promising penny stocks under $5 to buy. On February 17, Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer. Brian Piper joined the compa…
As the U.S. stock market edges higher with the S&P 500 reaching new milestones, investors are keenly watching for signals from the Federal Reserve and major tech earnings that could influence future trends. Amidst this backdrop, penny stoc…
As major stock indexes in the United States show mixed performance following two consecutive sessions of losses, investors are keeping a close eye on market movements and economic indicators. In this environment, identifying stocks priced…
As the United States market kicks off a holiday-shortened week with major stock indexes closing lower, investors are closely watching sectors like technology and precious metals, which have recently experienced notable declines. In this fl…
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways th…
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 20…
As December 2025 begins, U.S. stock indexes have slipped, with major tech and cryptocurrency-tied shares experiencing declines amid a broader risk-off sentiment in the market. Despite this cautious atmosphere, investors continue to explore…
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the Com…
Last Friday, the three most widely followed benchmark indexes closed a losing week. The tech-heavy Nasdaq, the S&P 500 and the Dow Jones slid 2.7%, 2% and 1.9%, respectively. Nasdaq witnessed its third straight week of losses. Softer corpo…
LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the Com…
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment pa…
(RTTNews) - Prelude Therapeutics Inc (PRLD) revealed Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's bottom line came in at -$19.73 million, or -$0.26 per share. This compar…
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 P…
Prelude Therapeutics, Incorporated Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F op…
Prelude Therapeutics, Incorporated Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients liv…
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinic…
As the United States stock market reaches record highs, driven by a tame inflation report and expectations of an interest rate cut, investors are exploring diverse opportunities across various sectors. Penny stocks, often associated with s…
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today.…
As the U.S. stock market navigates through a period of cautious optimism, with investors closely monitoring Federal Reserve developments and recent policy changes, attention turns to the potential within smaller-cap stocks. Penny stocks, a…
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare confe…
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Con…
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A…
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and esophageal cancer…
WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Glo…
Key Insights Given the large stake in the stock by institutions, Prelude Therapeutics' stock price might be vulnerable to their trading decisions The top 2 shareholders own 54% of the company Ownership research, combined with past performa…
Shell plc SHEL confirmed the recommencement of liquefied natural gas (LNG) cargo loading from its offshore Prelude facility in Australia. The colossal floating LNG production facility, located approximately 475 kilometers (300 miles) off A…
One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others. Already, cutting edge healthcare stocks are getting into the AI boom. Medical science has much to…